Shanghai Bio-heart Biological Technology Co., Ltd. (2185.HK)
HKSE - HKSE Delayed price. Currency in HKD
Add to watchlist
At close: 04:08PM HKT
| Previous close | 2.060 |
| Open | 2.060 |
| Bid | 2.080 x N/A |
| Ask | 2.100 x N/A |
| Day's range | 2.010 - 2.120 |
| 52-week range | 1.790 - 6.770 |
| Volume | |
| Avg. volume | 37,864 |
| Market cap | 527.375M |
| Beta (5Y monthly) | -0.47 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.780 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- PR Newswire
Bioheart (02185.HK) announces clinical result for Iberis-HTN at CIT 2023
Bioheart (02185.HK), together with its holding subsidiary Angiocare announces the clinical result for Iberis-HTN at China Interventional Therapeutics 2023. Iberis-HTN is a prospective, multicenter, blinded, randomized controlled trial to evaluate the safety and efficacy of the Iberis® Multi-Electrode Renal Artery Radiofrequency Ablation Catheter System for the treatment of primary hypertension (NCT02901704). The study was led by Academician Runlin GAO and Professor Xiongjing JIANG from Fuwai Hos
© 2024 Yahoo. All rights reserved.